Skip to content
Evoq Remedies logo

Evoq Remedies

543500 BSE
Price unavailable

Evoq Remedies (EVOQ) share price was ₹1.61 at the 28 Oct 2026 close; market capitalisation ₹4.05 Cr; sector Commercial Services. The share price fell 71.8% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Mar 2026 quarter, revenue was under ₹0.01 Cr, against ₹11.76 Cr a year earlier and net profit was −₹0.29 Cr, against ₹1.71 Cr a year earlier (compared with Mar 2025). Promoters held 0.02% of Evoq Remedies in Mar 2026, down 11.19 percentage points from Sep 2025. Its Tapetide Score is 48/100 (Average) as of 28 Oct 2026.

Close 28 Oct 2026 ₹1.61 −3.82 −70.35% 1Y

Key Fundamentals

SMECommercial ServicesServices
Market Cap
₹4.05 Cr
EBITDA
−₹1.45 Cr
Return on Equity
0.2%
Debt to Equity
0
Book Value
₹17.79
EPS (TTM)
—
52W High
₹5.16
52W Low
₹1.35

Price-based figures as of 28 Oct 2026, 15:30 IST · TTM

Peer Comparison

Services › Commercial Services › Trading & Distributors

Redington
₹350.3016.1027,386 Cr2.701.68%12.32%19.00%1,28,312 Cr1,504 Cr
MMTC
₹51.5417.307,731 Cr3.640.00%18.27%29.75%908 Cr447 Cr
MSTC
₹566.3017.013,987 Cr4.412.82%24.16%31.29%478 Cr234 Cr
Creative Newtech
₹1,171.1023.881,759 Cr4.390.05%18.15%26.34%2,794 Cr74 Cr
Pervasive Commodities
——1,104 Cr12.250.00%-0.05%0.02%40 Cr-0 Cr
RRP Defense
——810 Cr59.900.00%53.72%74.36%12 Cr-2 Cr
Evoq Remedies (this company)
——4 Cr0.090.00%0.20%0.29%——
Median 7 companies₹458.3017.161,759 Cr4.390.00%18.15%26.34%693 Cr154 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

48 Average
Overall score

Data confidence 84/100

Category scores

Quality Average 52
Returns, margins, earnings quality 22% weight
Valuation Good 56
Cheap vs sector & own history 24% weight
Growth Strong 98
Sales & profit trajectory 9% weight
Financial Health Good 64
Solvency, leverage, coverage 9% weight
Momentum Poor 6
Trend strength, vol-adjusted 12% weight
Ownership Poor 34
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is almost debt free.
  • Stock is trading at 0.11 times its book value
  • Debtor days have improved from 160 to 55.1 days.

Weaknesses

5
  • Company has low interest coverage ratio.
  • Promoter holding has decreased over last quarter: -11.2%
  • Promoter holding is low: 0.02%
  • Company has a low return on equity of 0.29% over last 3 years.
  • Contingent liabilities of Rs.6.55 Cr.

Technical Indicators

Oscillators

Bullish

Bearish
1
Neutral
5
Bullish
3

Overall

Bearish

Bearish
11
Neutral
5
Bullish
3

Moving Averages

Bearish

Bearish
10
Neutral
0
Bullish
0

Growth Rate

Revenue Growth
79.65% higher than 3Y

change over 1 year

Net Income Growth
-340% lower than 3Y

change over 1 year

Cash Flow Change
-375%

change over 1 year

EBITDA Margin Change
-534%

change over 1 year

Quarterly Results

Particulars Mar 2021Sep 2021Mar 2022Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026
Sales
2.76
4.93
11.85
15.79
4.6
3.9
0.15
0
11.76
25.51
0
Expenses
1.71
4.2
11.12
15.48
8.64
3.83
1.87
1.63
12.36
26.46
0.5
Operating Profit
1.05
0.73
0.73
0.31
-4.04
0.07
-1.72
-1.63
-0.6
-0.95
-0.5
OPM %
38.04%
14.81%
6.16%
1.96%
-87.83%
1.79%
-1146.67%
—
-5.1%
-3.72%
—
Other Income
0
0
0
0
6.02
0
2.26
0.01
2.4
1.06
0.19
Interest
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0.04
0.03
0.02
PBT
1.05
0.73
0.73
0.31
1.98
0.07
0.54
-1.62
1.76
0.08
-0.33
Tax %
22.86%
0%
50.68%
0%
33.84%
28.57%
29.63%
0%
2.27%
25%
-12.12%
Net Profit
0.81
0.73
0.36
0.31
1.31
0.05
0.38
-1.62
1.71
0.05
-0.29
EPS (₹)
11.57
10.43
0.26
0.23
0.96
0.04
0.28
-0.65
0.69
0.02
-0.12
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
3.25
9.07
10.02
16.78
20.39
4.05
11.76
25.51
Expenses
3.23
9.07
9.07
15.32
24.12
5.69
13.99
26.96
Operating Profit
0.02
0
0.95
1.46
-3.73
-1.64
-2.23
-1.45
OPM %
0.62%
0%
9.48%
8.7%
-18.29%
-40.49%
-18.96%
-5.68%
Other Income
0
0
0
0
6.02
2.26
2.41
1.25
Interest
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0.01
0.05
0.05
PBT
0.02
0
0.95
1.46
2.29
0.61
0.13
-0.25
Tax %
0%
—
25.26%
25.34%
29.26%
26.23%
30.77%
-4%
Net Profit
0.01
0
0.72
1.09
1.62
0.45
0.09
-0.24
EPS (₹)
0.14
0
10.29
0.8
1.19
0.33
0.04
-0.1
Div. Payout %
0%
—
0%
0%
0%
0%
0%
0%
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.01
0.01
0.01
13.6
13.6
13.6
24.9
24.9
Reserves
0.01
0.01
0.73
9.57
11.19
11.64
19.64
19.4
Borrowings
0
0.01
0
8.16
9.58
4.24
0
0.07
Other Liabilities
2.12
5.62
7.3
2
0.53
7.39
5.47
7.57
Total Liabilities
2.14
5.65
8.04
33.33
34.9
36.87
50.01
51.94
Fixed Assets
0
0
0
0
0.01
0.01
0.22
0.17
CWIP
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
Other Assets
2.14
5.65
8.04
33.33
34.89
36.86
49.79
51.77
Total Assets
2.14
5.65
8.04
33.33
34.9
36.87
50.01
51.94
Figures in ₹ Crores

Cash Flow

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0.01
-0.02
0.03
-26.43
-4.35
5.32
-14.62
-0.28
Investing
0
0
0
0
-0.01
-0.01
-0.26
0
Financing
0
0
0
29.49
1.42
-5.34
14.97
0.07
Net Cash Flow
0.01
-0.02
0.03
3.06
-2.94
-0.03
0.09
-0.21
Free Cash Flow
0.01
-0.02
0.03
-26.43
-4.36
5.31
-14.88
-0.28
CFO/EBITDA
50
—
3
-1,785
99
-334
654
19
Figures in ₹ Crores

Ratios

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
138
190
249
553
308
157
268
55.09
Inventory Days
3.39
2.42
6.97
20.66
38.33
732
61.9
23.92
Days Payable
240
227
315
32.05
—
767
97.59
10.89
Cash Conversion Cycle
-98.04
-34.3
-59.11
541
—
122
232
68.12
Working Capital Days
1.12
1.21
26.23
437
441
2,263
1,369
631
ROCE %
—
0%
246.75%
9.11%
6.97%
1.91%
0.35%
-0.56%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Evoq Remedies insights

54 extracted metrics + investor summaries across FY11–FY26.

Shareholding Pattern

Public94.57%Promot.0.02%Others5.41%As ofMar 2026

Documents

Frequently Asked Questions about Evoq Remedies

What does Evoq Remedies Ltd do?
Incorporated in 2010, EVOQ Remedies Ltd is in the pharmaceutical business.[1]
Where is Evoq Remedies Ltd (EVOQ) listed?
Evoq Remedies Ltd trades under code 543500 on the BSE.
Which sector does Evoq Remedies Ltd belong to?
Evoq Remedies Ltd is classified under the Commercial Services sector, in the Trading & Distributors industry.
What is the market capitalisation of Evoq Remedies Ltd?
Evoq Remedies Ltd has a market capitalisation of ₹4.05 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the 52-week high and low of Evoq Remedies Ltd?
Over the last 52 weeks Evoq Remedies Ltd has traded between ₹1.35 and ₹5.16 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Evoq Remedies Ltd?
Evoq Remedies Ltd reported a return on equity of 0.20%. Its debt-to-equity ratio is 0.00.

Company Information

Incorporated in 2010, EVOQ Remedies Ltd is in the pharmaceutical business.[1]

Website evoqremedies.com
Listed 2022-03-30
Face Value ₹ 10
Shares Outstanding 2,51,28,205

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/543500.md for Evoq Remedies Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Commercial Services stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month